The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.

开始日期2020-09-02

申办/合作机构

Virginia Commonwealth University

[+1]

NCT04447469 / Completed临床2/3期

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation

Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).

开始日期2020-07-27

申办/合作机构

Kiniksa Pharmaceuticals Ltd.

NCT04397497 / Unknown status临床2期

A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)

This study is a prospective, phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized patients with acute respiratory failure requiring oxygen supplementation in COVID- 19 pneumonia and a hyper-inflammatory status. The study will randomize patients to mavrilimumab or placebo, in addition to standard of care per local practice. The total trial duration will be 12 weeks after single mavrilimumab or placebo dose.

开始日期2020-05-22

申办/合作机构

Ospedale San Raffaele Srl

100 项与 Mavrilimumab 相关的临床结果

登录后查看更多信息

100 项与 Mavrilimumab 相关的转化医学

登录后查看更多信息

100 项与 Mavrilimumab 相关的专利（医药）

登录后查看更多信息

项与 Mavrilimumab 相关的文献（医药）

2022-09-02·Expert opinion on investigational drugs2区 · 医学

Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?

2区 · 医学

Review

作者: Harkins, Patricia ; Conway, Richard

INTRODUCTION:

Giant Cell Arteritis (GCA) is the most common systemic vasculitis worldwide. For decades, glucocorticoids have represented the mainstay of treatment, at the expense of toxic systemic effects owing to prolonged courses of high-dose treatment regimens. The search for effective drugs permitting lower glucocorticoid treatment regimens in GCA has been afrustrating one. The recent successful therapeutic application of tocilizumab, an interleukin-6 receptor inhibitor, has transformed the treatment of GCA and catalyzed research exploring other promising therapeutic targets.

AREAS COVERED:

This review explores emerging drugs in preclinical and clinical development for the management of GCA, in addition to synthesizing data on the current standard of care therapeutic agents. Drug therapies were identified by search of MEDLINE and PubMed in addition to trials from registries (clinicaltrials.gov, clinicaltrialsregister.eu, pubmed.gov) from theyear 2010.

EXPERT OPINION:

Tocilizumab has revolutionized the treatment of GCA. However, much remains to be learned about its optimal usage in GCA and asubstantial minority of pa tients do not achieve sustained glucocorticoid-free remission. Numerous exciting new agents are under investigation to fill this treatment gap in GCA, with the GM-CSF inhibitor mavrilimumab, and IL-12/23 blockade with ustekinumab providing promise through targeting the GCA pathogenic pathway in its proximal portion.

2022-09-01·Annals of the rheumatic diseases

Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli

Article

作者: Cavalli, Giulio ; Dagna, Lorenzo ; Campochiaro, Corrado ; Zangrillo, Alberto ; De Luca, Giacomo ; Della-Torre, Emanuel ; Ciceri, Fabio

A polemic in response to Ferraccioli et al is given.This article describes the open-label trials with sarilumab, tocilizumab, anakinra and mavrilimumab in patients with severe hyperinflamed COVID-19.In this article the IL-1 or GM-CSF seems a more promising approach since upstream blockade of the inflammatory cascade may allow a better control of cytokine storm-induced organ damage with a better safety profile are discussed.

2022-06-06·Polish archives of internal medicine

Recent advances in the diagnosis and therapy of large vessel vasculitis

Article

作者: Soy, Mehmet ; Atagunduz, Pamir ; Keser, Gokhan

Large vessel vasculitis (LVV), including Takayasu arteritis (TAK) and giant cell arteritis (GCA), causes granulomatous vascular inflammation mainly in large vessels, and is the most common primary vasculitis in adults. Vascular inflammation may evoke many clinical features including vision impairment, stroke, limb ischemia, and aortic aneurysms. The best way to diagnose LVV is to combine medical history, physical examination, various laboratory tests, and imaging modalities. Progress in imaging modalities facilitated early diagnosis and follow‑up of the disease activity. Conventional angiography is no longer the gold standard for the diagnosis of TAK. Similarly, temporal artery biopsy is no longer the only tool for diagnosing cranial GCA. In selected cases, color Doppler ultrasound may be used for this purpose. Despite some similarities, TAK and GCA differ in many aspects and they are different diseases. They also have different clinical subtypes. The presence of aortitis does not always implicate the diagnosis of TAK or GCA; infectious aortitis, as well as noninfectious aortitis associated with other autoimmune rheumatic diseases should be excluded. Treatment of LVV includes glucocorticoids (GCs), conventional immunosuppressive agents, and biological drugs. Tumor necrosis factor inhibitors are ineffective in GCA but effective in TAK. On the other hand, tocilizumab may be used to treat both diseases. Promising targeted therapies evaluated in ongoing clinical trials include, for example, anti‑IL‑12/23 (ustekinumab), anti‑IL‑17 (secukinumab), anti‑IL‑1 (anakinra), anti‑IL‑23 (guselkumab), anti‑cytotoxic T‑lymphocyte antigen 4 (abatacept), Janus kinase inhibitors (tofacitinib and upadacitinib), anti‑granulocyte / macrophage colony‑stimulating factor (mavrilimumab), and endothelin receptor (bosentan) therapies.

项与 Mavrilimumab 相关的新闻（医药）

2024-06-24

·GlobeNewswire-Health Care

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis

– Campaign to elevate experiences from the recurrent pericarditis community and provide resources to patients and caregivers – HAMILTON, Bermuda, June 24, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced a partnership with National Hockey League (NHL) Hall-of-Famer, Henrik Lundqvist, to raise awareness in support of patients suffering from recurrent pericarditis. Lundqvist has faced the challenges of living with this painful and debilitating chronic autoinflammatory cardiovascular disease. The campaign will kick off in September of this year. Pericarditis is marked by a profound inflammation of the pericardial tissue in the multi-layered sac that surrounds the heart. The associated sharp chest pain frequently requires urgent care and hospitalization, and patients often believe they are having a heart attack. Patients experiencing recurrent pericarditis flares suffer wide-ranging effects on quality of life, physical activity, and overall well-being. “Despite the significant impact of recurrent pericarditis on patients’ lives, the limited understanding of the disease often results in delayed diagnosis and treatment,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “We are honored to collaborate with Henrik Lundqvist to raise awareness of the realities of suffering from recurrent pericarditis. We believe this collaboration will help educate and inspire individuals to take proactive steps to access appropriate medical care early on to prevent future flares.” For more information on recurrent pericarditis, visit whatispericarditis.com. To learn about the first and only U.S. Food and Drug Administration-approved therapy for recurrent pericarditis, visit arcalyst.com. About Recurrent PericarditisRecurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data show that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. IMPORTANT SAFETY INFORMATION ABOUT ARCALYST ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.Medicines that affect the immune system may increase the risk of getting cancer.Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose. For more information about ARCALYST, talk to your doctor and see the Product Information. Forward-Looking StatementsThis press release contains forward-looking statements. In some cases, you can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: the timing of the campaign, our belief that our collaboration will help educate and inspire individuals to take proactive steps to access appropriate medical care early on to prevent future flares and our belief that all of our product candidates offer the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our and our partners’ achievements to be materially different from those expressed or implied by the forward-looking statements. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Every Second Counts! ® Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

疫苗

2024-06-17

·GlobeNewswire-Health Care

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and improve care quality – HAMILTON, Bermuda, June 17, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced its sponsorship of the American Heart Association’s new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis. “We are proud to sponsor the American Heart Association’s Addressing Recurrent Pericarditis initiative. Recurrent pericarditis is a rare, chronic, flaring disease, in which patients are frequently misdiagnosed or undertreated due to a lack of access to expert care. In addition to elevating awareness and knowledge around recurrent pericarditis, this initiative will also help strengthen overall care by working to improve processes for diagnosing, referring, and treating patients,” said John F. Paolini, M.D., Ph.D., FACC, Chief Medical Officer of Kiniksa. “Furthermore, this initiative will facilitate knowledge-sharing across a collaborative network of healthcare providers, with the objective of establishing a clear model to streamline patient access to expert care and improved outcomes nationwide.” Through the Addressing Recurrent Pericarditis initiative, the American Heart Association will establish a learning collaborative of champions at fifteen healthcare sites for recurrent pericarditis care. These champions will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions. The ultimate goal of the initiative is to improve outcomes and quality of life for recurrent pericarditis patients by disseminating best practices through national education, model sharing, abstract development, and patient- and physician-targeted podcasts and webinars. “Recurrent pericarditis symptoms can have significant impact on emotional health and quality of life, but they often go undiagnosed and untreated,” said Mariell Jessup, M.D., FAHA, Chief Science and Medical Officer of the American Heart Association. “This new initiative will share insights and best practices nationally to improve identification and treatment for patients with this disease.” Participating sites in the learning collaborative include: Ascension St. Thomas Heart (Nashville, Tennessee)Bluhm Cardiovascular Institute, Northwestern Medicine (Chicago, Illinois)Brigham & Women’s Hospital (Boston, Massachusetts)Cleveland Clinic (Cleveland, Ohio)Houston Medical Hospital (Houston, Texas)Knight Cardiovascular Institute Cardiology Clinic, Oregon Health & Science University (Portland, Oregon)Massachusetts General Hospital (Boston, Massachusetts)Mayo Clinic – Rochester (Rochester, Minnesota)My Cardiologist/CVAUSA (Miami, Florida)New York University Grossman School of Medicine (New York, New York)Pacific Heart Institute (Santa Monica, California)The Regents of the University of California Irvine (Irvine, California)University of Michigan (Ann Arbor, Michigan)University of Utah Hospital (Salt Lake City, Utah)University of Virginia (Charlottesville, Virginia) About Recurrent PericarditisRecurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data shows that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. Forward-Looking StatementsThis press release contains forward-looking statements. In some cases, you can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: the ultimate number of healthcare sites that will participate in the learning collaborative; our belief that the Addressing Recurrent Pericarditis initiative will (a) improve quality of care through identification, dissemination and implementation of best practices for the diagnosis and management of recurrent pericarditis, (b) elevate awareness and knowledge around recurrent pericarditis, (c) strengthen overall care by working to improve processes for diagnosing, referring and treating patients, and (d) facilitate knowledge-sharing across a collaborative network of healthcare providers to streamline patient access to expert care and improve outcomes nationwide; that the healthcare champions participating in the Addressing Recurrent Pericarditis initiative will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions with the ultimate goal of improving outcomes, quality of life, identification and treatment for recurrent pericarditis patients by disseminating insights and best practices; and our belief that all of our product candidates offer the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our and our partners’ achievements to be materially different from those expressed or implied by the forward-looking statements. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Every Second Counts! ® Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

AHA会议

2024-05-20

·生物制药小编

2024Q1高瓴药企持仓变动

近日，高瓴旗下专注于美国二级市场投资的基金HHLR ADVISORS, LTD在其13F报告中披露了2024年第一季度持仓明细。资金总量方面，从2023年Q4的49亿下滑到了2024Q1的46亿美元。持仓方面的变动主体主要关于是半导体及电商领域，尤其涉及ASML，台积电，英伟达，ADVANCED MICRO DEVICES等企业，一部分中概股企业继续遭到了大幅减持，保持着过去季度的减持趋势。而百济神州，传奇生物等作为大股东的生物制药企业则基本未有变动。尽管持仓变动主体并非生物制药行业，但是仍然有一部分涉及生物制药行业的大幅变动情况，本文将对此进行简单总结。被收购的RAYZEBIOHHLR于2023年Q3建仓了核药Biotech RAYZEBIO，而正巧BMS在2023年年末宣布要将RayzeBio收购，因此在2024年Q1完成相关收购流程后，这部分股份应当也被BMS买下了。如果单从购买时间进行简单分析，这场交易中HHLR应该实现了2倍左右增值。2023年Q3建仓时的价格应当在20美元左右，而BMS收购时，最终收购价来到了62.5美元。从技术角度来看，RAYZEBIO采用的是基于锕系的放射性同位素疗法，锕225释放的α粒子在人体组织内影响距离较短，但能量却很大，能够实现在一定范围内对癌细胞的可控杀伤。被清仓的NEUMORA THERAPEUTICSHHLR同样于2023年Q3建仓了AI精神疾病治疗公司NEUMORA THERAPEUTICS，但在2024Q1时清仓了该股。这家公司的主营业务主要是利用AI去开发新靶点机制的精神病药物。现在来看，这一决策无比正确，因为正好在4月15日时，该公司的核心管线之一的NMRA-266的1期临床试验遭到了FDA叫停。受到这一消息影响，该公司股价第二日跌去了17%。不过在此之前，其实这家公司还有另外一项值得深思的人事变动……虽然该公司没有声明这一点，但是3月份参会信息以及其后另外一家公司的财报信息显示：作为首席医学官（CMO）的Michael Gold博士已经离职加入了竞争对手之一的Compass担任首席研发官，他的履历强调了他在NEUMORA的工作，并在Asha Therapeutics担任咨询顾问的副职。而Michael Gold本人以前还是艾伯维的神经科学的VP，可能在NEUMORA的临床开发中具有举足轻重的地位，因此他的出走可能预示着NEUMORA THERAPEUTICS的临床存在一定问题。而迄今为止，该公司仍旧未找到下一个CMO……SAGIMET BIOSCIENCESHHLR同样于2023年Q3建仓了SAGIMET BIOSCIENCES，而本季度SAGIMET遭到了HHLR减持50%。SAGIMET BIOSCIENCES这家公司主要致力于新型脂肪酸合酶 (FASN) 抑制剂开发，我国的歌礼制药通过其全资子公司AP11 Limited领投了Sagimet的E轮融资，并获得了核心管线TVB-2640（歌礼代号ASC40）大中华区独家开发权益。从股价走势来看，该公司在1月份TVB-2640的II期临床数据在NASH（非酒精性脂肪肝）上相当优异，也带动了一波股价上涨，但随后就逐步降低。原因可能是多方面的，TVB-2640的效果虽然优秀，一些数据（如甘油三酯）似乎并不明朗，但是同赛道竞品中3月已有THR-β激动剂REZDIFFRA（resmetirom）上市，GLP-1R激动剂带来的降维打击也对该赛道整体提出了更多的疑问。KINIKSA PHARMACEUTICALS2023年HHLR Q4清仓了KINIKSA PHARMACEUTICALS，现在又再建仓了KINIKSA PHARMACEUTICALS。KINIKSA PHARMACEUTICALS目前的主要开发管线共有三条：已经上市的IL-1抑制剂Arcaylst，CD40单抗abipurbart，GM-CSF抗体Mavrilimumab。mavrilimumab的开发相对不太顺利，正在等待其他合作伙伴，实际管线也没有开发到III期以后，这可能也是GM-CSF抗体领域的通病，早期关于新冠和自免领域的尝试都失败了。CD40单抗abipurbart似乎出现于首个猪心移植等免疫排异的应用中，可能这里也有相关合作，另外主要的开发方向是干燥综合征，目前进入III期临床。已上市首款应用于心包炎的IL-1抑制剂Arcaylst是该公司管线中较为值得期待的，仅仅2024年第一季度ARCALYST的净产品收入就为7890万美元，销售额呈现出不断上升的趋势，美国21个学术机构心包炎专科心脏病专家在复发性心包炎治疗方面的转变，并表明自2021年ARCALYST商业化用于复发性心包炎以来，与皮质类固醇相比，ARCALYST的使用比例不断增加。这对于被授权方的华东医药来说也是好消息。未来有潜力成长为重磅炸弹。总结总的来说，虽然此次在生物制药领域变动相对不大，但仍然有许多可以挖掘的地方。比如说NEUMORA THERAPEUTICS公司这类新兴精神疾病公司的未来发展是否会因为核心管线之一出现问题而逐渐式微，FASN抑制剂是否能够开辟多领域赛道等等。另外高瓴投资的ArriVent在Q1上市也值得观察未来的发展情况。参考来源：各个公司官网

并购财报

100 项与 Mavrilimumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09930	Mavrilimumab	-	DB12534

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
SARS-CoV-2 急性呼吸道疾病	临床3期	智利	Kiniksa Pharmaceuticals Ltd.	2021-05-16
炎症	临床3期	美国	Kiniksa Pharmaceuticals Ltd.	2020-07-16
新型冠状病毒感染	临床2期	意大利	Ospedale San Raffaele Srl	2020-05-22
成人呼吸窘迫综合征	临床2期	意大利	Ospedale San Raffaele Srl	2020-05-22
呼吸衰竭	临床2期	美国	Kiniksa Pharmaceuticals Ltd.	2020-05-20
巨细胞动脉炎	临床2期	美国	Kiniksa Pharmaceuticals Ltd.	2018-09-20
巨细胞动脉炎	临床2期	澳大利亚	Kiniksa Pharmaceuticals Ltd.	2018-09-20
巨细胞动脉炎	临床2期	比利时	Kiniksa Pharmaceuticals Ltd.	2018-09-20
巨细胞动脉炎	临床2期	克罗地亚	Kiniksa Pharmaceuticals Ltd.	2018-09-20
巨细胞动脉炎	临床2期	爱沙尼亚	Kiniksa Pharmaceuticals Ltd.	2018-09-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03827018 (CTgov)	临床2期	巨细胞动脉炎	70	prednisone+mavrilimumab (Mavrilimumab)	鹽餘積衊壓獵繭積積夢(積鏇顧顧網鬱窪膚窪廠) = 選觸醖艱齋構齋範襯鹹構獵壓鏇觸願醖積壓觸 (蓋糧膚網壓繭網餘齋網, 憲憲築鬱顧築齋鑰鑰遞 ~ 廠遞積簾遞範鹽廠積淵) 更多	-	2023-10-17
				placebo+prednisone (Placebo)	鹽餘積衊壓獵繭積積夢(積鏇顧顧網鬱窪膚窪廠) = 艱顧鑰製鬱淵獵顧憲繭構獵壓鏇觸願醖積壓觸 (蓋糧膚網壓繭網餘齋網, 齋蓋壓繭艱窪築觸範蓋 ~ 範簾壓艱衊遞積夢簾構) 更多
NCT03827018 (Pubmed) 人工标引	临床2期	巨细胞动脉炎	70	mavrilimumab	膚襯餘蓋淵艱獵積築齋(齋淵鏇築壓餘壓醖簾網) = 醖繭積築餘淵鏇積鹹膚窪積顧淵顧齋觸網鑰醖 (範齋糧積遞衊齋獵膚獵 ) 更多	积极	2022-03-09
				Placebo	膚襯餘蓋淵艱獵積築齋(齋淵鏇築壓餘壓醖簾網) = 願襯簾鬱鏇範蓋製衊網窪積顧淵顧齋觸網鑰醖 (範齋糧積遞衊齋獵膚獵 ) 更多
NCT04463004 (CTgov)	临床2期	呼吸衰竭 \| 新型冠状病毒感染 \| 炎症	2	Mavrilimumab (Intervention)	餘壓窪醖糧夢鬱網醖鬱(齋遞獵淵鬱淵構鹽淵繭) = 壓製憲襯鏇構齋夢夢鏇遞鹽願獵淵獵鬱淵願醖 (鹹顧鬱鑰簾餘蓋構構醖, 齋獵齋鑰蓋憲鑰網築艱 ~ 鹹網製鑰醖簾憲簾衊鑰) 更多	-	2021-08-11
				Placebos (Control)	餘壓窪醖糧夢鬱網醖鬱(齋遞獵淵鬱淵構鹽淵繭) = 膚齋餘製艱網壓積鬱糧遞鹽願獵淵獵鬱淵願醖 (鹹顧鬱鑰簾餘蓋構構醖, 衊鏇膚鹽積觸構獵簾鬱 ~ 壓遞醖簾構繭襯憲顧簾) 更多
Phase 2 Trial of Mavrilimumab (EULAR2021)	临床2期	巨细胞动脉炎 C-reactive protein \| erythrocyte sedimentation rate	70	Mavrilimumab 150mg	積簾窪鑰繭淵膚網餘簾(蓋鹹憲膚窪衊積廠繭襯) = 艱獵製廠衊製築繭製獵構艱鹽網淵觸選膚襯製 (網襯築鬱鏇廠窪艱築鹽 ) 更多	-	2021-06-02
				Placebo	積簾窪鑰繭淵膚網餘簾(蓋鹹憲膚窪衊積廠繭襯) = 積艱壓範鬱膚積觸願艱構艱鹽網淵觸選膚襯製 (網襯築鬱鏇廠窪艱築鹽 ) 更多
EULAR2021	临床2期	巨细胞动脉炎	70	Mavrilimumab 150 mg	廠鏇繭觸鹽廠獵夢襯襯(餘餘選願選範淵膚獵構) = 艱憲製簾鹹壓網繭醖淵繭鑰鏇繭選鑰遞廠餘範 (壓構鏇選選艱憲繭遞鏇, 67.9 ~ 91.6)	积极	2021-06-02
				Placebo	廠鏇繭觸鹽廠獵夢襯襯(餘餘選願選範淵膚獵構) = 糧蓋夢蓋構積製願壓齋繭鑰鏇繭選鑰遞廠餘範 (壓構鏇選選艱憲繭遞鏇, 29.6 ~ 67.3)
NCT04492514 \| NCT04463004 \| NCT04399980 (Pubmed) 人工标引	临床2期	新型冠状病毒感染	40	Mavrilimumab	壓觸觸夢襯憲襯製齋襯(顧衊鏇構廠繭鹽網餘夢) = 築壓廠襯夢糧簾鬱網窪觸衊襯艱顧選齋網鹹衊 (襯觸鬱齋鏇繭衊網襯襯 )	不佳	2021-06-01
				Placebo	壓觸觸夢襯憲襯製齋襯(顧衊鏇構廠繭鹽網餘夢) = 淵膚廠構遞選膚鹽艱範觸衊襯艱顧選齋網鹹衊 (襯觸鬱齋鏇繭衊網襯襯 )
NCT04399980 (CTgov)	临床2期	呼吸衰竭 \| 新型冠状病毒感染 \| 炎症	40	Mavrilimumab (Intervention)	願蓋蓋鏇積淵鏇鹹獵遞(鏇淵繭淵鹹衊簾範蓋獵) = 廠鏇襯獵願積夢選壓選襯糧襯鹹膚襯簾鹹繭淵 (艱憲夢顧鬱鬱蓋膚鏇遞, 壓壓遞齋窪襯鬱艱鹽構 ~ 憲夢廠艱鬱憲簾鹹網廠) 更多	-	2021-05-13
				Placebos (Control)	願蓋蓋鏇積淵鏇鹹獵遞(鏇淵繭淵鹹衊簾範蓋獵) = 鏇構願鑰齋膚齋鑰積築襯糧襯鹹膚襯簾鹹繭淵 (艱憲夢顧鬱鬱蓋膚鏇遞, 夢網繭構糧構觸觸鏇餘 ~ 範艱選獵製網築齋遞範) 更多
NCT04447469 (Corporate Publications) 人工标引	临床2期	新型冠状病毒感染	116	Standard of Care+Mavrilimumab	衊壓醖艱壓窪範蓋壓鹹(簾齋蓋衊淵獵廠餘選淵) = 憲鹽製糧淵獵齋網齋繭衊憲膚築範鏇廠鑰壓築 (襯憲製壓艱遞簾鬱襯鹽 ) 更多	积极	2021-04-12
				Placebo+Standard of Care	衊壓醖艱壓窪範蓋壓鹹(簾齋蓋衊淵獵廠餘選淵) = 衊顧築醖願範選夢範夢衊憲膚築範鏇廠鑰壓築 (襯憲製壓艱遞簾鬱襯鹽 ) 更多
NCT04399980 (Corporate Publications) 人工标引	临床2期	新型冠状病毒感染 \| 炎症	40	mavrilimumab	齋網窪壓廠憲窪餘淵製(淵積範願蓋網淵製憲壓) = 蓋膚簾繭襯範憲淵夢壓積蓋窪觸觸鬱鏇廠鏇憲 (繭構衊觸醖壓艱窪簾顧 ) 更多	积极	2020-12-22
				Placebo	齋網窪壓廠憲窪餘淵製(淵積範願蓋網淵製憲壓) = 選壓觸蓋醖簾憲網鹹鏇積蓋窪觸觸鬱鏇廠鏇憲 (繭構衊觸醖壓艱窪簾顧 ) 更多
NCT01712399 (Pubmed \| Arthritis Rheumatol)	临床2期	类风湿关节炎	442	Mavrilimumab	衊夢壓窪網願獵憲築壓(鹹鏇憲選網餘壓觸鏇糧) = 築衊鹹獵襯繭廠艱獵鏇簾獵選鏇衊窪餘襯廠選 (簾壓襯壓築繭構衊蓋醖 ) 更多	-	2018-05-01